Level Biotechnology Inc. (TPEX:3118)

Market Cap	1.09B +3.7%
Revenue (ttm)	736.59M +0.7%
Net Income	79.70M +23.0%
EPS	2.44 +22.6%
Shares Out	32.45M
PE Ratio	13.71
Forward PE	n/a
Dividend	1.80 (5.37%)
Ex-Dividend Date	Jun 12, 2025

Volume	1,331
Average Volume	34,547
Open	32.90
Previous Close	33.50
Day's Range	32.90 - 33.85
52-Week Range	29.50 - 34.70
Beta	0.30
RSI	60.50
Earnings Date	Mar 10, 2026

About Level Biotechnology

Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It markets and distributes biomedical precision equipment. The company also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the biotech, pharmaceutical, medical device, animal health, and agrichemical industries. The company was founded in 1989 and is headquartered in New Taipei Ci...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1989
• Employees: 132
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 3118

Financial Performance

In 2025, Level Biotechnology's revenue was 736.59 million, an increase of 0.72% compared to the previous year's 731.35 million. Earnings were 79.70 million, an increase of 22.97%.